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Abstract
Background: Bleeding is the most common and worrisome adverse effect of warfarin therapy. One of the factors that might
increase bleeding risk is initiation of interacting drugs that potentiate warfarin. We sought to evaluate whether initiation of
an antidepressant increases the risk of hospitalization for gastrointestinal bleeding in warfarin users.
Methodology/Principal Findings: Medicaid claims data (1999–2005) were used to perform an observational case-control
study nested within person-time exposed to warfarin in those $18 years. In total, 430,455 warfarin users contributed
407,370 person-years of warfarin use. The incidence rate of hospitalization for GI bleeding among warfarin users was 4.48
per 100 person-years (95% CI, 4.42–4.55). Each gastrointestinal bleeding cases was matched to 50 controls based on index
date and state. Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram
(OR=1.73 [95% CI, 1.25–2.38]), fluoxetine (OR=1.63 [95% CI, 1.11–2.38]), paroxetine (OR=1.64 [95% CI, 1.27–2.12]),
amitriptyline (OR=1.47 [95% CI, 1.02–2.11]). Also mirtazapine, which is not believed to interact with warfarin, increased the
risk of GI bleeding (OR=1.75 [95% CI, 1.30–2.35]).
Conclusions/Significance: Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had
an increased risk of hospitalization for gastrointestinal bleeding. However, the elevated risk with mirtazapine suggests that a
drug-drug interaction may not have been responsible for all of the observed increased risk.
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Introduction
Warfarin is highly effective in reducing the risk of thromboem-
bolic events. With an estimated two million people initiating
warfarin therapy each year in the US [1], it is one of the top 20
drugs prescribed in the US. Bleeding is the most common and
worrisome adverse effect of warfarin therapy, with an annual
incidence of major bleeding of 4–8% [2,3]. One of the factors that
might increase bleeding risk is initiation of interacting drugs that
potentiate warfarin.
Depression often coexists with cardiovascular disease, and
nearly 7% of warfarin users are co-prescribed antidepressants
[4]. Commonly used drug-drug interaction compendia in the US
warn about potential interactions between warfarin and several
selective serotonin reuptake inhibitors (SSRIs), serotonin-norepi-
nephrine reuptake inhibitors (SNRIs), and tricyclic antidepressants
(TCAs) [5–7]. These agents might increase bleeding risk by
inhibiting CYP2C9 (mainly fluoxetine and fluvoxamine [8]),
which metabolizes the more potent (S)-enantiomer of warfarin;
by inhibiting CYP1A2 or CYP3A4, which metabolizes the less
potent (R)-enantiomer of warfarin; and/or by blocking serotonin
reuptake by platelets, which may result in impaired platelet
aggregation (mainly SSRIs [9–15]).
Three observational studies have evaluated the risk of bleeding
during exposure to antidepressants in warfarin and coumarin users
[4,16,17]. However, their results have conflicted. In two studies, a
statistically significantly increased bleeding risk was found [16,17],
while in a third no increased bleeding risk was found [4]. Further,
in all of the studies, investigators assumed that bleeding risk was
constant after initiation of the antidepressant. In contrast, we
would expect that the GI bleeding risk in warfarin users would be
the highest shortly after initiation of an antidepressant, and would
decline subsequently because of depletion of susceptibles (i.e.,
patients who are susceptible to bleeding from the drug-drug
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e21447interaction develop the event early) [18]. Therefore, we sought to
evaluate whether warfarin users who initiated antidepressants had
a higher risk of GI bleeding shortly after antidepressant initiation.
Methods
Settings and design
This observational case-control study used pre-existing Medi-
caid data of California, Florida, New York, Ohio, and Pennsylva-
nia from 1999 to 2005. In total, these five states include
approximately 13 million Medicaid enrollees, which account for
about 35% of the Medicaid population. The data were obtained
from the Centers for Medicare and Medicaid Services (CMS) [19],
as were linked Medicare data on all Medicare-Medicaid dual
eligibles. This data source contains health care claims for hospital,
medical, and outpatient pharmaceutical coverage linked to
enrollment information. A series of quality assurance analyses
found low rates of abnormalities in this data source, suggesting
that the data are of high quality [20].
This study was approved by the University of Pennsylvania’s
Committee on Studies Involving Human Beings, which granted
waivers of informed consent and Health Insurance Portability and
Accountability Act authorization.
Eligible subjects and person-time in this case-control
study
Only person-time exposed to warfarin (outpatient prescriptions
only) in those aged 18 years and older between January 1, 1999
and December 1, 2005 was included. We assumed that the
duration of a warfarin prescription was equivalent to the number
of tablets dispensed with a maximum duration of 30 days.
Prescriptions that were filled on the same day were combined. We
used a maximum of 30 days because prescriptions covered by
Medicaid in the five study states are typically dispensed in 30-day
increments. This assumption was confirmed by examining the
frequency distribution of the number of pills dispensed and the
number of days between subsequent warfarin prescriptions for
each warfarin user. Nonetheless, we also performed a sensitivity
analyses assuming that each warfarin prescription was equivalent
to twice the number of tablets dispensed with maximum duration
of 60 days. The rationale for this sensitivity analyses was to allow
for non-adherence, and include events that may have occurred
shortly after cessation of therapy.
The observation period ended with either a hospitalization for
GI bleeding, the presumed end of the last warfarin prescription,
discontinuation of Medicaid eligibility, or end of the study period,
whichever occurred first. Further, we excluded all warfarin users
who filled a prescription for an antidepressant of interest 90 days
before or on the same days as their first observed warfarin
prescription, because the goal of this study was to evaluate the
safety of initiation of SSRIs, SNRIs, and TCAs in patients already
receiving warfarin. In a secondary analysis, we evaluated whether
duration of warfarin use influenced the ORs of interest. The
rationale is that chronic warfarin users, defined as those with
$three warfarin prescriptions on the index date, were expected to
have been on a stable warfarin dose and have less frequent
International Normalized Ratio (INR) measurements, and there-
fore to be more likely to experience a bleeding complication due to
a drug-drug interaction compared to a new warfarin initiator. In
addition, because re-initiators might have a different GI bleeding
risk than continuing warfarin users, we conducted a sensitivity
analysis in which we excluded follow-up time after $180 days
between consecutive warfarin prescriptions.
Identification of cases and controls
Cases consisted of all individuals age 18 and above hospitalized
with a principal or non-principal International Classification of
Diseases, 9
th Revision (ICD-9) code for GI bleeding during eligible
person-time exposed to warfarin. ICD-9 codes used to identify
gastrointestinal bleeding events were: ulcer of esophagus with
hemorrhage (530.21), gastric ulcer with hemorrhage (531.1*,
531.2*, 531.4*, 531.6*), duodenal ulcer with hemorrhage (532.1*,
532.2*, 532.4*, 532.6*), peptic ulcer with hemorrhage (533.1*,
533.2*, 533.4*, 533.6*), gastrojejunal ulcer with hemorrhage
(534.1*, 534.2*, 534.4*, 534.6*), gastritis and duodenitis with
hemorrhage (535.01, 535.11, 535.21, 535.31, 535.41, 535.51,
535.61), angiodysplasia or dieulafoy lesion of stomach and
duodenum with hemorrhage (537.83, 537.84), diverticul of
intestine with hemorrhage (562.02, 562.03, 562.12, 562.13),
angiodysplasia or dieulafoy lesion of intestine with hemorrhage
(569.85, 569.86), and gastrointestinal hemorrhage (578.*). These
codes have been shown to have a positive predictive value of 81%
[21]. The index date for a case was the hospital admission date.
Fifty controls were selected at random for each case during
eligible person-time exposed to warfarin, matched on index date
and state, using incidence density sampling [22]. Eligible controls
consisted of warfarin users who had not been hospitalized with a
diagnosis code for GI bleeding by the day of the hospitalization of
the case. The index date assigned to each control was the index
date of their matched case.
Co-exposure to an antidepressant
SSRIs, SNRIs, and TCAs that were listed as potentially
interacting agents with warfarin in commonly used US drug
interaction compendia (Drug Facts [5], MicroMedex 2.0 [6], or
Drug Interactions Analysis and Management 2010 [7]) were
considered as study agents of interest. To evaluate whether there
might be residual confounding, mirtazapine was chosen as a
reference drug. Mirtazapine has, as far as we know, not been
suggested to interact with warfarin. We considered a warfarin user
co-exposed to antidepressant of interest if a prescription was filled
29 days prior or on the index-date. The rationale for this was that
the average duration of an antidepressant prescription was 30
days. Warfarin users exposed to two or more different antidepres-
sants in the index date were excluded.
Each case and control exposed to one antidepressant on the
index date was classified into one of three categories based on
number of days between the index date and their first observed
antidepressant prescription, i.e., 0–29 (first antidepressant pre-
scription), 30–59 (second antidepressant prescription), 60–119
days (third and fourth antidepressant prescription). After a gap of
$180 days between consecutive antidepressant prescriptions, the
numbering was restarted. In a sensitivity analysis, we excluded
follow-up time after a $180 day gap between consecutive
prescriptions. To avoid having an insufficient number of events
in multivariable models, we did not evaluate antidepressants with
fewer than eleven exposed cases or controls for any of the time
categories.
Ascertainment of potential confounding variables
The appendix lists all of the potential confounding variables that
were ascertained. The following four classes of potential
confounding factors were defined as of the index date: 1)
demographic factors; 2) chronic diseases, defined as diagnosis
ever before the index date; 3) use of agents that could increase or
decrease the bleeding risk; and 4) use of agents that could
potentially interact with warfarin as defined by MicroMedex [6],
defined as a prescription in the prior 30 days.
Antidepressant-Warfarin Interaction
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We first measured the incidence rate of GI bleeding in the cohort
of warfarin users. Next, we calculated the odds ratios (ORs) and
95% confidence intervals (CI) for the association between initiation
of an antidepressant and hospital admission for GI bleeding using
conditional logistic regression. In the minimally adjusted model, we
adjusted for age, gender, race, and number of prior warfarin
prescriptions (classified as 0, 1, 2, or 3+). We then examined each
potential confounding factor individually, and, if the factor changed
any of the ORs of interest by $5%, it was considered a confounder
andretainedinthe fullyadjustedmodel[23].Todeterminewhether
this confounder selection approach might have missed measured
Table 1. Characteristics on the index date of cases of gastrointestinal bleeding and controls exposed to warfarin.
Variables Cases Controls
N=13,026 N=653,209 Matched Lower Upper
N % N % OR* 95% CI 95% CI
Age
18–50 849 6.52 85,456 13.08 Reference
51–60 1,208 9.27 79,866 12.23 1.53 1.40 1.67
60–70 2,336 17.93 123,848 18.96 1.91 1.76 2.06
70–80 3,901 29.95 179,088 27.42 2.21 2.05 2.38
81+ 4,732 36.33 184,951 28.31 2.61 2.43 2.81
Gender, male 4,472 34.33 238,512 36.51 0.91 0.88 0.94
Race
Caucasian 7,423 56.99 388,804 59.52 Reference
African American 2,305 17.70 94,479 14.46 1.28 1.22 1.35
Other/Unknown 3,298 25.32 169,926 26.01 1.02 0.97 1.06
Nursing home resident 3,742 28.73 121,666 18.63 1.96 1.88 2.04
Dementia
{ 3,757 28.84 127,462 19.51 1.71 1.65 1.78
Renal disease
{ 3,893 29.89 94,605 14.48 2.55 2.46 2.65
Liver disease
{ 2,827 21.70 90,035 13.78 1.77 1.69 1.84
Prior GI bleeding
{ 4,641 35.63 110,158 16.86 2.82 2.72 2.93
Use of acetaminophen
1 3,189 24.48 113,315 17.35 1.55 1.49 1.61
Use of NSAID
1 721 5.54 22,101 3.38 1.68 1.55 1.81
Use of levofloxacin
1 818 6.28 18,097 2.77 2.36 2.20 2.54
Use of PPI
1 3,300 25.33 123,180 18.86 1.48 1.42 1.54
Number of prior
warfarin prescriptions
0 1,537 11.80 28,539 4.37 3.17 3.00 3.35
1 957 7.35 28,350 4.34 2.00 1.87 2.14
2 746 5.73 28,846 4.42 1.54 1.43 1.66
3+ 9,786 75.13 567,474 86.87 Reference
Citalopram
1 162 1.24 7,314 1.12 1.11 0.95 1.30
Escitalopram
1 146 1.12 7,109 1.09 1.03 0.87 1.22
Fluoxetine
1 114 0.88 5,490 0.84 1.04 0.87 1.26
Paroxetine
1 258 1.98 11,932 1.83 1.09 0.96 1.23
Sertraline
1 316 2.43 13,850 2.12 1.15 1.03 1.29
Venlafaxine
1 77 0.59 4,133 0.63 0.94 0.75 1.17
Mirtazapine
1 152 1.17 6,538 1.00 1.17 1.00 1.38
Amitriptyline
1 122 0.94 5,001 0.77 1.22 1.02 1.47
Doxepin
1 22 0.17 531 0.08 2.10 1.37 3.21
Nortriptyline
1 20 0.15 1,147 0.18 0.88 0.56 1.36
CI=confidence interval; GI=gastrointestinal; OR=odds ratio; NSAID=non-steroidal anti-inflammatory drug; PPI=proton pump inhibitor.
*Adjusted for matching variables, i.e., index date and state.
{Ever in the past.
{Either an outpatient diagnosis for GI bleeding during warfarin therapy or a hospital admission for GI bleeding before initiating warfarin therapy, excluding the day prior
to and the index date.
1Prescription dispensed 0–29 days prior to the index date.
doi:10.1371/journal.pone.0021447.t001
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with a saturated model that included all potential confounders.
Results
In total, 430,455 warfarin users contributed 407,370 person-
years of warfarin use. The incidence rate of hospitalization for GI
bleeding was 4.48 per 100 person-years (95% CI, 4.42–4.55). After
the exclusion of 110,600 warfarin users (26%) who had filled a
prescription for an antidepressant 0–89 days prior to their first
warfarin prescription and 121 cases (0.9%) and 3369 controls
(0.5%) who were exposed to two or more antidepressants on the
index date, 13,026 cases of GI bleeding and 653,209 controls
remained in the analysis. Table 1 presents the baseline
characteristics of cases and controls.
The minimally and fully adjusted ORs for the association
between initiation of an antidepressant and GI bleeding for each of
the three exposure categories of interest (first, second, or third or
fourth antidepressant prescription) are presented in Table 2 and 3.
During the a priori defined primary duration category for a drug-
drug interaction (i.e., first antidepressant prescription) the
minimally adjusted ORs ranged from 1.51 to 2.49 and were all
statistically significant except for nortriptyline (Table 2). After
adjusting for confounders that changed any of the ORs of interest,
all ORs were attenuated and ranged from 1.18–1.75 (Table 3).
The adjusted association between GI bleeding and initiating of
citalopram (OR=1.73), fluoxetine (OR=1.63), paroxetine
(OR=1.64), amitriptyline (OR=1.47), and the reference agent
mirtazapine (OR=1.75) remained statistically elevated. In fully
adjusted analyses of the second and third or fourth prescription, no
statistically significant associations were observed, except for
amitriptyline during the third or fourth prescription (OR=1.61).
The results of the fully adjusted model were similar to the
saturated model (data not shown). Extending the maximum
duration of a warfarin prescription to 60 days, excluding warfarin
users with a gap of $180 days between consecutive warfarin
prescriptions, and antidepressant users with a gap of $180 days
between consecutive antidepressant prescriptions gave similar
results as those shown in Table 3 (data not shown).
Exclusion of warfarin users who were nursing home residents
resulted in statistically significant elevated odds immediately after
escitalopram initiation (first prescription OR=1.60, 95% CI:
1.01–2.55; Table 4).
Initiation of antidepressants resulted in slightly higher fully-
adjusted ORs for the first antidepressant prescription in chronic
warfarinusers compared toall warfarin users (citalopram: OR=1.98,
95% CI: 1.37–2.88; escitalopram: OR=1.32, 95% CI: 0.87–2.00;
fluoxetine: OR=1.98, 95% CI: 1.29–3.04; paroxetine: OR=1.53,
95% CI: 1.10–2.13, sertraline: OR=1.28, 95% CI: 0.90–1.81;
venlafaxine: OR=1.37, 95% CI: 0.74–2.54; amitriptyline:
OR=2.00, 95% CI: 1.35–2.97; nortriptyline: OR=1.48, 95%
CI: 0.65–3.40; mirtazapine: OR=2.07, 95% CI: 1.47–2.92).
Discussion
We found that warfarin users who initiated citalopram,
fluoxetine, paroxetine, amitriptyline, or mirtazapine had approx-
imately a 1.5-fold odds of serious GI bleeding during their first
antidepressant prescription compared with warfarin users who did
not fill a prescription for an antidepressant. Further, we found, as
expected, that the risk of GI bleeding in warfarin users generally
appeared to decline after the first antidepressant prescription
period. However, the elevated odds ratio for mirtazapine, which is
not believed to interact with warfarin, suggests that a drug-drug
interaction may not have been responsible for all of the observed
increased risk.
Three prior studies have evaluated the risk of GI bleeding in
warfarin users co-exposed to antidepressants. In the first case-
control study, use of antidepressants in the past 42 days could not
be studied because of small number of co-exposed cases, and use in
the past 90 days was not associated with hospitalization for upper
GI bleeding in warfarin users (fluoxetine/fluvoxamine OR=1.2,
95% CI: 0.8–1.7; other SSRIs OR=1.1, 95% CI: 0.9–1.4;
secondary TCAs OR=0.7, 95% CI: 0.4–1.4) [4]. Thus while this
study could not examine an early rise in risk with antidepressant
initiation, results are consistent with no increased risk after the first
antidepressant prescription. In a second case-control study,
coumarin users hospitalized for GI bleeding had no statistically
Table 2. Minimally adjusted association between initiation of an antidepressant agent (exposed versus unexposed) and
hospitalization for gastrointestinal bleeding in warfarin users.
Variables 0 to 29 days 30 to 59 days 60 to 119 days
(1
st prescription)
* (2
nd prescription)
* (3
rd or 4
th prescription)
*
OR Lower Upper OR Lower Upper OR Lower Upper
95% CI 95% CI 95% CI 95% CI 95% CI 95% CI
Citalopram 2.28 1.66 3.13 1.31 0.80 2.16 1.58 1.07 2.34
Escitalopram 1.58 1.10 2.27 1.31 0.82 2.10 1.27 0.86 1.88
Fluoxetine 1.94 1.34 2.83 1.06 0.55 2.06 0.84 0.45 1.56
Paroxetine 1.94 1.51 2.49 1.49 1.03 2.14 1.30 0.93 1.81
Sertraline 1.51 1.15 1.98 1.49 1.05 2.11 1.48 1.10 1.98
Venlafaxine 1.82 1.13 2.93 0.77 0.32 1.86 1.80 1.09 2.97
Amitriptyline 1.66 1.16 2.39 0.98 0.51 1.90 1.84 1.18 2.88
Nortriptyline 1.66 0.78 3.54 No data
{ No data
{
Mirtazapine 2.49 1.86 3.33 0.92 0.52 1.63 1.34 0.90 2.00
*Adjusted for age, gender, race, and number of prior warfarin prescriptions filled on the index date.
{Insufficient number of exposed cases or controls to analyze.
doi:10.1371/journal.pone.0021447.t002
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to SSRIs in the past 30 days [16]. However, this study assumed
that the risk after initiating an SSRI remains constant, and
therefore would have likely have missed an initial increased risk
if present. In a small cohort study, warfarin users co-exposed
to SSRIs had a 3.49-fold (95% CI: 1.37–8.91) hazard of
hospitalization for bleeding, but this study adjusted for few clinical
variables [16].
While some studies have shown that SSRIs themselves are
associated with bleeding even without warfarin [9,11,12,14], not
all studies have found this [10,15]. In our study, several of the
SSRIs were associated with GI bleeding, but there did not seem to
be a relationship with affinitity for the serotonin reuptake
transporter (paroxetine.sertraline.fluoxetine.citalopram [24]).
Therefore, our data do not support the hypothesis that blocking of
serotonin reuptake of platelets is responsible for the observed
associations.
Our study had several limitations. The main limitation was the
potential for residual confounding by unmeasured factors, such as
depression and its severity, smoking, alcohol use, body mass area,
and/or use of over the counter medications. Therefore, it remains
questionable whether the observed increased bleeding risk during
the first antidepressant prescription is due to a drug-drug
interaction or the result unmeasured confounding (i.e., warfarin
Table 4. Association between initiation of an antidepressant agent (exposed versus unexposed) and hospitalization for
gastrointestinal bleeding in warfarin users, after exclusion of nursing home residents.
Variables 0 to 29 days 30 to 59 days 60 to 119 days
(1
st prescription)
* (2
nd prescription)
* (3
rd or 4
th prescription)
*
OR Lower Upper OR Lower Upper OR Lower Upper
95% CI 95% CI 95% CI 95% CI 95% CI 95% CI
Citalopram 1.83 1.18 2.86 1.09 0.51 2.31 1.52 0.91 2.56
Escitalopram 1.60 1.01 2.55 1.36 0.70 2.64 0.95 0.51 1.78
Fluoxetine 1.88 1.16 3.07 0.68 0.25 1.83 0.87 0.39 1.94
Paroxetine 1.58 1.14 2.19 1.68 1.10 2.55 1.29 0.86 1.95
Sertraline 1.37 0.98 1.94 1.51 0.98 2.34 1.41 0.96 2.07
Venlafaxine 1.48 0.78 2.81 0.59 0.15 2.39 2.01 1.09 3.69
Amitriptyline 1.50 1.01 2.23 0.88 0.43 1.77 1.77 1.10 2.84
Nortriptyline 1.81 0.84 3.87 No data
{ No data
{
Mirtazapine 2.57 1.60 4.11 0.63 0.20 1.99 1.34 0.63 2.85
*Adjusted for age, gender, race, number of prior warfarin prescriptions filled on the index date, nursing home, use of dementia, liver disease, prior gastrointestinal bleed,
renal disease, use of acetaminophen, use of levofloxacin, and proton pump inhibitors.
{Insufficient number of exposed cases or controls to analyze.
doi:10.1371/journal.pone.0021447.t004
Table 3. Fully adjusted association between initiation of an antidepressant agent (exposed versus unexposed) and hospitalization
for gastrointestinal bleeding in warfarin users.
Variables 0 to 29 days 30 to 59 days 60 to 119 days
(1
st prescription)
* (2
nd prescription)
* (3
rd or 4
th prescription)
*
OR Lower Upper OR Lower Upper OR Lower Upper
95% CI 95% CI 95% CI 95% CI 95% CI 95% CI
Citalopram 1.73 1.25 2.38 1.05 0.63 1.73 1.24 0.84 1.85
Escitalopram 1.19 0.82 1.71 1.01 0.63 1.63 0.95 0.64 1.41
Fluoxetine 1.63 1.11 2.38 0.80 0.41 1.57 0.72 0.38 1.35
Paroxetine 1.64 1.27 2.12 1.29 0.90 1.87 1.07 0.77 1.49
Sertraline 1.18 0.90 1.56 1.23 0.87 1.75 1.19 0.89 1.60
Venlafaxine 1.43 0.88 2.31 0.59 0.24 1.45 1.31 0.79 2.17
Amitriptyline 1.47 1.02 2.11 0.82 0.42 1.59 1.61 1.03 2.53
Nortriptyline 1.45 0.68 3.12 No data
{ No data
{
Mirtazapine 1.75 1.30 2.35 0.64 0.36 1.13 0.95 0.63 1.42
*Adjusted for age, gender, race, number of prior warfarin prescriptions filled on the index date, nursing home, use of dementia, liver disease, prior gastrointestinal bleed,
renal disease, use of acetaminophen, use of levofloxacin, and proton pump inhibitors.
{Insufficient number of exposed cases or controls to analyze.
doi:10.1371/journal.pone.0021447.t003
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warfarin users). However, during the third or fourth antidepressant
prescription most of the ORs were close to 1, suggesting either that
confounding by unmeasured factors did not have a major effect,
depletion of susceptibles, or that depression treatment was
associated with a reduced risk. Another limitation is the relative
limited number of individuals that initiated antidepressant
therapy, which resulted in wide 95% CI and limited our ability
to study all drugs and all exposure windows of interest. Further, for
some of the agents, the point estimates were elevated without
statistically significance.
In conclusion, our finding suggest that there is an increased risk
of GI bleeding after initiation of citalopram, fluoxetine, paroxe-
tine, amitriptyline, and mirtazapine, and possible venlafaxine and
nortriptyline. However, it remains debatable whether the observed
increased bleeding risk during the first antidepressant prescription
is due to a drug-drug interaction or the characteristics of patients
receiving these agents. Regardless of mechanisms, increased
clinical vigilance is prudent for patients on warfarin who initiate
an antidepressant drug.
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